

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	ozanimod
Brand Name	Zeposia®
Dosage Form(s)	0.23 mg, 0.46 mg, and 0.92 mg oral capsules
Manufacturer	Bristol-Myers Squibb Canada
Submission Type	New Submission
Use Reviewed	Zeposia is used to treat adult patients with the relapsing and remitting form of multiple sclerosis (RRMS).
Common Drug Review (CDR)	Yes, the CDR recommended: Do Not Reimburse . Visit the CDR website for more details: www.cadth.ca/node/88649 .
Provincial Review	The DBC now screens drug submissions under review by the CDR to determine whether or not a full DBC review is necessary, based on past DBC reviews, recommendations, and existing PharmaCare coverage. If a full DBC review is determined to not be required, the Ministry's drug coverage decision will be based on the CDEC recommendation and an internal review only. The DBC screened ozanimod in August 2020. The DBC advised that because ozanimod is similar to some of the other drugs used for the treatment of RRMS, the Ministry may accept the CDEC's recommendation for ozanimod. Subsequently the CDR also recommended not to list for RRMS.
Drug Coverage Decision	Non-Benefit
Date	July 26, 2022
Reason(s)	Drug coverage decision is consistent with the CDEC recommendation. <ul style="list-style-type: none"> The drug did not demonstrate advantages over comparators with respect to efficacy, and quality of life.

	<ul style="list-style-type: none"> • Due to the lack of comparative data and the limitations of the available evidence, the clinical benefit of treatment with ozanimod was identified as being uncertain. • At the submitted price ozanimod was not considered cost-effective for RRMS.
Other Information	None

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council \(DBC\)](#) gives advice to the Ministry. The DBC looks at:

- whether the drug is safe and effective
- advice from a national group called the [Common Drug Review \(CDR\)](#)
- what the drug costs and whether it is a good value for the people of B.C.
- ethical considerations involved with covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes PharmaCare coverage decisions by taking into account:

- the existing PharmaCare policies, programs, and resources
- the evidence-informed advice of the DBC
- the drugs already covered by PharmaCare that are used to treat similar medical conditions
- the overall cost of covering the drug

Visit [The Drug Review Process in B.C. - Overview](#) and [Ministry of Health - PharmaCare](#) for more information.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.